Funakoshi Yohei, Yakushijin Kimikazu, Ohji Goh, Hojo Wataru, Sakai Hironori, Watanabe Marika, Kitao Akihito, Miyata Yoshiharu, Saito Yasuyuki, Kawamoto Shinichiro, Yamamoto Katsuya, Ito Mitsuhiro, Koyama Taiji, Imamura Yoshinori, Kiyota Naomi, Matsuoka Hiroshi, Mori Yasuko, Minami Hironobu
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe 650-0017, Japan.
Division of Infection Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Hospital and Graduate School of Medicine, Kobe 650-0017, Japan.
Vaccines (Basel). 2022 Jun 17;10(6):965. doi: 10.3390/vaccines10060965.
Anti-CD20 antibodies react with CD20 expressed not only on malignant B cells, but also on normal B cells. It has been reported that patients treated with anti-CD20 antibodies had an insufficient response to two-dose mRNA SARS-CoV-2 vaccination. To investigate the efficacy of a third dose in these patients, we investigated serum IgG antibody titers for the S1 protein after a third vaccination in 22 patients treated with the anti-CD20 antibody who failed two-dose vaccination. Results showed that overall, 50% of patients seroconverted. Although no patient who received the third dose within 1 year of the last anti-CD20 antibody administration showed an increase in S1 antibody titer, 69% of patients who received the third dose more than 1 year after the last anti-CD20 antibody administration seroconverted. Our data show that a third dose of vaccination is effective in improving the seroconversion rate in patients treated with the anti-CD20 antibody who failed standard two-dose vaccination.
抗CD20抗体不仅能与恶性B细胞上表达的CD20发生反应，也能与正常B细胞上的CD20发生反应。据报道，接受抗CD20抗体治疗的患者对两剂mRNA新冠疫苗接种反应不足。为了研究第三剂疫苗对这些患者的疗效，我们调查了22例接受抗CD20抗体治疗且两剂疫苗接种失败的患者在接种第三剂疫苗后针对S1蛋白的血清IgG抗体滴度。结果显示，总体而言，50%的患者发生了血清转化。虽然在最后一次抗CD20抗体给药后1年内接种第三剂疫苗的患者中，没有患者的S1抗体滴度升高，但在最后一次抗CD20抗体给药1年多后接种第三剂疫苗的患者中，69%发生了血清转化。我们的数据表明，第三剂疫苗接种对于提高接受抗CD20抗体治疗且标准两剂疫苗接种失败的患者的血清转化率是有效的。
